Agilent Technologies
corporateWebsite
Fund rating
0.0 / 35
0 published reviews
No per-dimension scores yet.
Published reviews
About
Named as an existing investor in the evidence concerning single-cell analysis; strategically relevant to a transcriptomics and drug-perturbation data platform.